422 related articles for article (PubMed ID: 28363192)
21. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs.
Kaur R; Garg T; Malik B; Gupta UD; Gupta P; Rath G; Goyal AK
Drug Deliv; 2016; 23(3):882-7. PubMed ID: 24870203
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel-Loaded Cholesterol-PEG Co-Modified Poly (n-Butyl) Cyanoacrylate Nanoparticles for Antitumor Drug Pulmonary Delivery: Preparation, Characterization, and in vivo Evaluation.
Hu X; Yang F; Liao Y; Li L; Zhao G; Zhang L
Int J Nanomedicine; 2020; 15():5361-5376. PubMed ID: 32801694
[TBL] [Abstract][Full Text] [Related]
23. Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition.
Liao Q; Yip L; Chow MYT; Chow SF; Chan HK; Kwok PCL; Lam JKW
Int J Pharm; 2019 Apr; 560():144-154. PubMed ID: 30731259
[TBL] [Abstract][Full Text] [Related]
24. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery.
Sung JC; Padilla DJ; Garcia-Contreras L; Verberkmoes JL; Durbin D; Peloquin CA; Elbert KJ; Hickey AJ; Edwards DA
Pharm Res; 2009 Aug; 26(8):1847-55. PubMed ID: 19407933
[TBL] [Abstract][Full Text] [Related]
25. Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation.
Garg T; Goyal AK; Rath G; Murthy RS
Pharm Dev Technol; 2016 Dec; 21(8):951-960. PubMed ID: 26334961
[TBL] [Abstract][Full Text] [Related]
26. Nanocrystals embedded in chitosan-based respirable swellable microparticles as dry powder for sustained pulmonary drug delivery.
Ni R; Zhao J; Liu Q; Liang Z; Muenster U; Mao S
Eur J Pharm Sci; 2017 Mar; 99():137-146. PubMed ID: 27988327
[TBL] [Abstract][Full Text] [Related]
27. Interfacial Phenomenon Based Biocompatible Alginate-Chitosan Nanoparticles Containing Isoniazid and Pyrazinamide.
Kushwaha K; Dwivedi H
Pharm Nanotechnol; 2018; 6(3):209-217. PubMed ID: 29938624
[TBL] [Abstract][Full Text] [Related]
28. Development of an inhalable, stimuli-responsive particulate system for delivery to deep lung tissue.
Abbas Y; Azzazy HM; Tammam S; Lamprecht A; Ali ME; Schmidt A; Sollazzo S; Mathur S
Colloids Surf B Biointerfaces; 2016 Oct; 146():19-30. PubMed ID: 27244047
[TBL] [Abstract][Full Text] [Related]
29. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
Momin MAM; Tucker IG; Das SC
Int J Pharm; 2018 Oct; 550(1-2):398-417. PubMed ID: 30179703
[TBL] [Abstract][Full Text] [Related]
30. The safety of ethambutol dihydrochloride dry powder formulations containing chitosan for the possibility of treating lung tuberculosis.
Ahmad MI; Nakpheng T; Srichana T
Inhal Toxicol; 2014 Dec; 26(14):908-17. PubMed ID: 25472479
[TBL] [Abstract][Full Text] [Related]
31. Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections.
Momin MAM; Tucker IG; Doyle CS; Denman JA; Sinha S; Das SC
Int J Pharm; 2018 Apr; 541(1-2):26-36. PubMed ID: 29458207
[TBL] [Abstract][Full Text] [Related]
32. Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide.
Debnath SK; Saisivam S; Debanth M; Omri A
PLoS One; 2018; 13(1):e0190976. PubMed ID: 29370192
[TBL] [Abstract][Full Text] [Related]
33. Promising Chitosan-Coated Alginate-Tween 80 Nanoparticles as Rifampicin Coadministered Ascorbic Acid Delivery Carrier Against Mycobacterium tuberculosis.
Scolari IR; Páez PL; Sánchez-Borzone ME; Granero GE
AAPS PharmSciTech; 2019 Jan; 20(2):67. PubMed ID: 30627867
[TBL] [Abstract][Full Text] [Related]
34. Development of Novel Chitosan Microcapsules for Pulmonary Delivery of Dapsone: Characterization, Aerosol Performance, and In Vivo Toxicity Evaluation.
Ortiz M; Jornada DS; Pohlmann AR; Guterres SS
AAPS PharmSciTech; 2015 Oct; 16(5):1033-40. PubMed ID: 25652730
[TBL] [Abstract][Full Text] [Related]
35. [Development of Inhalable Dry Powder Formulations Loaded with Nanoparticles Maintaining Their Original Physical Properties and Functions].
Okuda T
Yakugaku Zasshi; 2017; 137(11):1339-1348. PubMed ID: 29093369
[TBL] [Abstract][Full Text] [Related]
36. A triple combination 'nano' dry powder inhaler for tuberculosis: in vitro and in vivo pulmonary characterization.
Chogale MM; Dhoble SB; Patravale VB
Drug Deliv Transl Res; 2021 Aug; 11(4):1520-1531. PubMed ID: 34041715
[TBL] [Abstract][Full Text] [Related]
37. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection.
Arora S; Haghi M; Loo CY; Traini D; Young PM; Jain S
Mol Pharm; 2015 Jun; 12(6):2001-9. PubMed ID: 25923171
[TBL] [Abstract][Full Text] [Related]
38. Development and Characterization of Nanoembedded Microparticles for Pulmonary Delivery of Antitubercular Drugs against Experimental Tuberculosis.
Goyal AK; Garg T; Rath G; Gupta UD; Gupta P
Mol Pharm; 2015 Nov; 12(11):3839-50. PubMed ID: 26436948
[TBL] [Abstract][Full Text] [Related]
39. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.
Ohashi K; Kabasawa T; Ozeki T; Okada H
J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349
[TBL] [Abstract][Full Text] [Related]
40. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
